Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR L861Q
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
therascreen® EGFR RGQ PCR Kit (5)
therascreen® EGFR RGQ PCR Kit (5)
Associations
(23)
News
Trials
Search handles
@DrJNaidoo
@Latinamd
@StephenVLiu
@dipeshuprety4
@esinghimd
Search handles
@DrJNaidoo
@Latinamd
@StephenVLiu
@dipeshuprety4
@esinghimd
Filter by
Latest
1year
2/ @LeXiuning @MDAndersonNews on EGFR mutations: ▪️EGFR mutations ~10-20% NSCLC pts in Europe/N America, & up to 50% of patients in Asia ▪️Exon 19 del & exon 21 L858R most common (~85-90%) ▪️🔑 Most frequent uncommon mutations to know: G719X, S768I, L861Q, & exon 20 insertions (@esinghimd)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
over1year
Retrospective analysis of osimertinib in 50 pts with atypical #EGFR NSCLC in #JTOCRR. Median time to d/c 17.2m for L861Q, 7.8m for G719X, 1.5m for exon 20 insertion. Afatinib is the approved standard for atypical; amivantamab and mobocertinib for ex20ins. https://t.co/kQiqpEJYTZ (@StephenVLiu)
over 1 year ago
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib) • Gilotrif (afatinib) • Rybrevant (amivantamab-vmjw) • Exkivity (mobocertinib)
over1year
🚨🚨 Check out our latest collaboration: #UNICORN: UNcommon EGFR mutations: International Case series on efficacy of #osimertinib in 1st liNe J Bair et al. ▶️N=60, G719X L861Q & T790M ▶️ORR 61%, mOS 24.5m. compound EGFR+ did better @EGFRResisters #lcsm https://t.co/7CqrcJpiXr (@Latinamd)
over 1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib)
over1year
In this multi-center, retrospective study @JTOonline for uncommon EGFR mutation (n=60), osimertinib demonstrated an ORR of 61% (44% for denovo T790M, 47% for G719X ORR & 80% for L861Q) Md PFS 9.5 mo Md DOR 17.4 mo & Md OS of 24.5 mo #LCSM @OncoAlert https://t.co/XxvURqgISg (@dipeshuprety4)
over 1 year ago
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib)
over1year
Osimertinib in NSCLC w uncommon EGFR mutns @JTOonline: - 60pt retrosp study, overall ORR 66% - G719X ORR 47% mPFS 8.8m mDOR 9.1m - L861Q ORR 80% mPFS 16m mDOR 16m - de novo T790M ORR 44% mPFS 12.7m mDOR 46.2m ?⬇️ORR T790M than expected, important study https://t.co/B3kpq7AKbR (@DrJNaidoo)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib)
2years
Retrospective report @Annals_Oncology from the national Network of Genomic Medicine in Germany describes 856 NSCLC cases with atypical #EGFR mutations. Includes G719X, S7681, L861Q, exon 20 insertions and rare point mutations with clinical outcomes. #LCSM https://t.co/2benHuhrA7 (@StephenVLiu)
2 years ago
Clinical data • Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X
almost3years
#L861Q #exon21 #egfr #LCSM Currently on Osi 180mg + Abraxane (4th line in one year) Can you move backwards to never before used Afantinib? @DevikaDasMD @Tony_Calles @HenningWillers @LeciaSequist @StephenVLiu (@mindyjoyphoto)
almost 3 years ago
EGFR (Epidermal growth factor receptor)
|
EGFR L861Q
|
albumin-bound paclitaxel
over3years
#OncoAlert Characterization of #EGFR L861Q mutation @JTOonline @IASLC. L861Q was ~ 3% of EGFR mutations (30% had compound mutations, usually in exon 18). Retrospectively, better outcomes with 2nd gen EGFR TKIs compared to 1st or 3rd generation. #LCSM https://t.co/NW4ZJD0Zmy (@StephenVLiu)
over 3 years ago
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L861Q • EGFR exon 18 mutation
over3years
#OncoAlert In vitro work showed #EGFR L861Q relies on asymmetric dimerization with prominent HER2 phosphorylation (thus, greater efficacy with pan-HER TKIs). Potential for greater personalization of therapy here. Great work by @michael_offin @HelenaYu923 @MLadanyi #LCSM (@StephenVLiu)
over 3 years ago
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR L861Q
4years
@JackWestMD Patient question. Is there any data for pulse dose osimertinib for a oatient with egfr L861Q mutant nscca w brain Mets through 80 mg daily of tagrisso, already treated w gamma knife and whole brain? Would adding ramucirimab or avastin be a consideration? Thanks (@andrea20372113)
4 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR L861Q
|
Avastin (bevacizumab) • Tagrisso (osimertinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login